Friday, June 5, 2026

Social Media Addiction, Talcum Powder Dockets Lead 532 New Weekly Filings Ending June 5, 2026

Federal courts saw a total of 532 new mass-tort actions during the week ending June 5, 2026, with the bulk of the volume concentrated in litigation targeting consumer tech and personal care products. In the social media addiction docket (MDL 3047)—which alleges that tech platforms employ addictive designs that cause psychological injuries in adolescents—plaintiffs filed 83 new complaints. Much of this activity came from Wright & Schulte LLC (35) and Keller Postman LLC (19), alongside filings attributed to Social Media Addiction (0) and the Law Offices of Charles H Johnson (0). Meanwhile, the talcum powder litigation (MDL 2738), focusing on claims that asbestos-contaminated talc products cause ovarian cancer, brought in 60 new cases. The filings in this docket involved Talcum Powder (0), Ashcraft Gerel LLP (0), The Miller Firm LLC (0), and Frazer PLC (0).

Activity also remained high in the pharmaceutical sector, where the Depo-Provera birth control shot litigation (MDL 3140)—which alleges that the contraceptive injection causes brain tumors—expanded by 52 new cases. Plaintiff firms pushing this litigation forward included Aylstock Witkin Kreis Overholtz PLLC (10), MCH Law PLLC (0), and Hochman Law Firm PLLC (0), as well as Depo-Provera (0). Similarly, the Suboxone dental injury docket (MDL 3092)—which alleges that the sublingual opioid addiction treatment causes severe tooth decay—registered 46 new lawsuits. These cases were filed by ASK Law (0) and Seigel Law (0), with Suboxone (0) also recorded on the docket.

Rounding out the week's most active dockets, the hair relaxer litigation (MDL 3060), which alleges that chemical hair-straightening products cause uterine cancer, grew by 41 new filings. The legal push was represented by Johnson Law Group (0), Douglas & London (0), and Peiffer Wolf (0), alongside Hair Relaxer (0). As summer progresses, practitioners will want to keep a close eye on whether these filings maintain their current velocity or if pending motion practice in the social media docket begins to chill new filings.

New Study Explores Gut Microbiome Dysbiosis in Full-Term Infants with Necrotizing Enterocolitis

A new study published in PubMed on June 9, 2026, offers critical insights into the gut microbiome profiles of full-term infants diagnosed with necrotizing enterocolitis (NEC). Historically focused on preterm populations, this research compared mature infants who developed the inflammatory bowel disease to healthy, breastfed controls, discovering that the abundance of key bacteria like Bacteroidetes and Bacteroides was significantly depleted in infants with NEC. These findings contribute to the growing scientific understanding of microbial dysbiosis, which serves as a central issue in the coordinated Preterm Infant Nutrition Products Liability Litigation (MDL 3026), where plaintiffs are currently seeking to establish general causation in pretrial proceedings before Judge Rebecca R. Pallmeyer. In those consolidated actions, plaintiffs allege that cow's milk-based infant formulas disrupt the neonatal gut microbiome and cause the development of NEC.

Real-World Safety Study Evaluates Optic Ischemic Neuropathy Risk in GLP-1 Users

A new comparative study published in PubMed on June 8, 2026, provides critical real-world safety data concerning the risk of non-arteritic anterior ischemic optic neuropathy (NAION) in patients receiving incretin-based therapies. The research compared the incidence of the rare, vision-threatening condition among users of glucagon-like peptide-1 (GLP-1) receptor agonists and other treatments, addressing the ongoing medical debate over whether these popular weight-loss and diabetes drugs are causally linked to NAION. The publication arrives as litigation expands in the Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation (MDL 3163), which was centralized in the U.S. District Court for the Eastern District of Pennsylvania under Judge Karen S. Marston. Attorneys tracking the docket anticipate that these findings will shape upcoming expert disclosures and Daubert challenges as the parties litigate the scientific validity of the plaintiffs' design defect and failure-to-warn claims.